Helus Pharma, the operating name for Cybin Inc., closed its public offering of 10,309,280 common shares. The company sold the shares at US$4.85 each to raise gross proceeds of approximately US$50 million. Cantor and Barclays managed the offering as joint book-runners. The transaction finalized on June 25, 2026.
The company will use the net proceeds to accelerate its clinical development programs. This capital funds the Phase 3 trial of HLP003 for major depressive disorder. The proceeds also support the HLP004 program for generalized anxiety disorder and the HLP005 program. This funding allows Helus Pharma to advance its late-stage clinical trials and general corporate objectives.